7035-10-1

Basic information

• Product Name: 2-CHLORO-2-METHOXYBENZYL ALCOHOL 97
• Synonyms: 2-CHLORO-2-METHOXYBENZYL ALCOHOL 97;2-CHLORO-2-METHOXYBENZYL ALCOHOL 97%;(5-Chloro-2-methoxyphenyl)methanol;BENZENEMETHANOL, 5-CHLORO-2-METHOXY
• CAS NO: 7035-10-1
• Molecular Formula: C₈H₉ClO₂
• Molecular Weight: 173.6168
• Mol File: 7035-10-1.mol
• Article Data: 16

Chemical Properties

• Melting Point: 56-61 °C(lit.)
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-2-METHOXYBENZYL ALCOHOL 97(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-2-METHOXYBENZYL ALCOHOL 97(7035-10-1)
• EPA Substance Registry System: 2-CHLORO-2-METHOXYBENZYL ALCOHOL 97(7035-10-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 7035-10-1(Hazardous Substances Data)

Usage

Uses

(5-Chloro-2-methoxyphenyl)methanol is used in the synthesis of α- or β-aryl- and γ-aryl-γ-benzyl-γ-butyrolactones.

Upstream product

• 5330-38-1 4-chloro-2-hydroxymethylphenol 
• 74-88-4 methyl iodide 
• 29568-33-0 2-methoxy-5-chlorobenzoyl chloride 
• 3438-16-2 5-chloro-2-methoxybenzoic acid 
• 635-93-8 5-chlorosalicyclaldehyde 
• 7035-09-8 5-chloro-2-methoxybenzaldehyde 
• 33924-48-0 methyl 5-chloro-2-methoxybenzoate 
• 68216-06-8 ethyl 5-chloro-2-methoxybenzoate 

Downstream Products

• 7035-11-2 4-chloro-2-chloromethyl-1-methoxy-benzene 
• 1071618-35-3 (5-chloro-2-methoxybenzyl)(triphenyl)phosphonium bromide 
• 7048-38-6 (5-chloro-2-methoxy-phenyl)-acetonitrile 
• 872181-38-9 2-(5-chloro-2-methoxybenzyloxy)-6-fluorobenzonitrile 
• 1444384-32-0 1-(5-chloro-2-methoxybenzyl)-1H-indazole-5-carboxylic acid methyl ester 
• 58735-58-3 2-(bromomethyl)-4-chloro-1-methoxybenzene 
• 202822-68-2 3-[(5-Chloro-2-methoxyphenyl)methyl]-5-[4-(trifluoromethyl)-phenyl]-1,3,4-oxadiazol-2(3H)-one 
• 202821-81-6 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)-phenyl]-1,3,4-oxadiazol-2(3H)-one 

Relevant articles and documents

METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY

Disclosed are methods of treating creatine transporter deficiency, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that increases transport of a substrate by a mutant or wild-type creatine transporter. Also disclosed are methods of increasing transport of guanidinoacetic acid or a salt thereof across the blood-brain barrier of a mammal, and methods of decreasing accumulation or the concentration of guanidinoacetic acid or a salt thereof in a mammalian cell.

Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor

The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, so far, few selective SMS2 inhibitors and their pharmacological activities were reported. In this study, a class of 2-benzyloxybenzamides were discovered as novel SMS2 inhibitors through scaffold hopping and structural optimization. Among them, Ly93 as one of the most potent inhibitors exhibited IC50 values of 91 nM and 133.9 μM against purified SMS2 and SMS1 respectively. The selectivity ratio of Ly93 was more than 1400-fold for purified SMS2 over SMS1. The in vitro studies indicated that Ly93 not only dose-dependently diminished apoB secretion from Huh7 cells, but also significantly reduced the SMS activity and increased cholesterol efflux from macrophages. Meanwhile, Ly93 inhibited the secretion of LPS-mediated pro-inflammatory cytokine and chemokine in macrophages. The pharmacokinetic profiles of Ly93 performed on C57BL/6J mice demonstrated that Ly93 was orally efficacious. As a potent selective SMS2 inhibitor, Ly93 significantly decreased the plasma SM levels of C57BL/6J mice. Furthermore, Ly93 was capable of dose-dependently attenuating the atherosclerotic lesions in the root and the entire aorta as well as macrophage content in lesions, in apolipoprotein E gene knockout mice treated with Ly93. In conclusion, we discovered a novel selective SMS2 inhibitor Ly93 and demonstrated its anti-atherosclerotic activities in vivo. The preliminary molecular mechanism-of-action studies revealed its function in lipid homeostasis and inflammation process, which indicated that the selective inhibition of SMS2 would be a promising treatment for atherosclerosis.

A BMS - 191011 synthetic method

The invention relates to a synthetic method for a compound BMS-191011. The method comprises the following steps: taking 4-trifluoromethyl benzoyl hydrazine as a raw material and performing steps of oxidative carbonylation, methyl protection, halogenation, amination, deprotection and the like to prepare BMS-191011. The synthetic method adopts a CO balloon for replacing phosgene, so that the reaction toxicity is reduced and the reaction operability is improved. The method has the characteristics of simple and easily available raw materials, mild reaction conditions and simple operation process.